NDAORALCAPSULE, EXTENDED RELEASE
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PINDAC (pinacidil) is an oral extended-release capsule approved in 1989 for cardiovascular indications. The specific mechanism of action and therapeutic indication are not detailed in available data, limiting full characterization of its clinical role. It represents a mature small-molecule product nearing loss of exclusivity.
LOE Approaching
Product is in late-stage maturity with LOE approaching, signaling reduced commercial investment and potential team consolidation in coming years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PINDAC offers limited career growth given its LOE-approaching status and zero linked job openings. Roles on this product focus on defending market share and managing decline rather than growth or innovation, making it less attractive for career advancement than growth-stage assets.
Brand ManagerField Sales Representative
Worked on PINDAC at PleoPharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.